Loading
A phase 1/2 trial of TQB2930, TQB3616, Fulvestrant, Capecitabine, Vinorelbine and Eribulin in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT06202261 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 154 participants planned, started 2023-04-13 and due to reach its primary completion in 2026-12. Interventions recorded: TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tablets and Vinorelbine tartrate injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TQB3616, Sino Biopharmaceutical (Chia Tai Tianqing), Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TQB2930, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Eribulin, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/